Regular, precise assessments of RA disease activity, as recommended by EULAR and ACR, are important to improving patient outcomes1, 2, 3. Vectra DA – the only multi-biomarker blood test validated to measure RA disease activity– provides an objective and reproducible measure of disease activity in both seropositive and seronegative patients4. Vectra DA simultaneously measures 12 proteins consistently associated with RA disease activity, integrating them into a single, quantitative score to help inform patient management decisions.
This presentation will review the potential clinical applications of Vectra DA in the management of RA, with a specific focus on findings from recent studies presented at the Annual Rheumatology Meeting held in DC.
Potential clinical applications of Vectra DA include:
- Tracking changes in disease activity over time (baseline assessment and on-going tracking)
- Measuring RA disease activity in response to change in therapy
- Assessing RA disease activity in patients with common comorbidities
- Clarifying RA disease activity when clinical disease assessment may be challenging (symptoms vs. labs, MD vs. patient assessment)
- Facilitating discussion with patients reluctant to change treatment
- Identifying unsuspected disease activity
Vectra DA is validated for use in adults diagnosed with RA. Test results are intended to aid in the assessment of disease activity in RA patients when used in conjunction with standard clinical assessment. This test is not intended or validated to diagnose RA.
1 Saag, Kenneth G, et al. American College of Rheumatology 2008 Recommendations for the Use of Nonbiologic and Biologic Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis. Arthritis & Rheumatism (Arthritis Care & Research). 2008 June 15; 59(6): 762–784
2 Smolen, Josef S, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Annals of Rheumatic Diseases. 2010; 69: 631-637
3 Bakker, M F, et al. Tight control in the treatment of rheumatoid arthritis: efficacy and feasibility. Annals of Rheumatic Diseases. 2007; 66(Suppl III): iii56–iii60
4 Curtis JR, van der Helm-van Mil AH, Knevel R, et al. Validation of a novel multi-biomarker test to assess rheumatoid arthritis disease activity. Arthritis Care Res. 2012; doi:10.1002/acr.21767 [Epub ahead of print].
Eric Sasso, MD, Vice President Medical and Scientific Affairs, Crescendo Bioscience
Dr. Eric Sasso is the Vice President, Medical and Scientific Affairs at Crescendo Bioscience. Dr. Sasso was previously a Medical Director at Abbott Laboratories where he worked in Early Immunology clinical development, and for seven years in Humira Medical Affairs, in rheumatology and dermatology.
Dr. Sasso is an Adjunct Associate Professor at the University of Washington and is board certified in Internal Medicine and Rheumatology.
Who Should Attend?
Health Care Professionals involved in the treatment of rheumatoid arthritis
Vectra DA is the only multi-biomarker blood test for rheumatoid arthritis (RA) disease activity that integrates 12 key proteins consistently associated with RA disease activity into a single objective score to help physicians make more informed treatment decisions. Vectra DA testing is performed at Crescendo Bioscience’s state-of-the-art laboratory and test results are reported back within 7-10 days. Physicians can receive test results via standard mail, fax or via a private web portal, VectraView. Vectra DA is available in the U.S. in 49 states and pending laboratory licensure in NY. For more information on Vectra DA, please visit, http://www.vectra-da.com/.
Crescendo Bioscience®, Inc.
Crescendo Bioscience is a molecular diagnostics company focused in rheumatology and located in South San Francisco, CA. Crescendo Bioscience develops quantitative, objective, biology-based tests to provide rheumatologists with deeper clinical insights to help enable more effective management of patients with autoimmune and inflammatory diseases. For more information, please visit the company’s website at http://www.crescendobio.com/.